Study Title

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Study Details

Description:

This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Sponsor:

Ariceum Therapeutics GmbH

Contacts:

Ariceum Therapeutics Clinical Trials

clinical@ariceum-therapeutics.com

+49 30 94 89 3360

Government Study Link:

NCT06939036 - Click here to see study on

ClinicalTrials.gov

Drug Details

225Ac-SSO110
Isotope(s):
    ACTINIUM-225
    Radioisotope: Ac-225
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 9.9 Days
    Decay Mode: ALPHA, GAMMA
    Energy: 5.8-8.4 MeV
    Range: 47-85 micrometers
    Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
    Status: Clinical Trials Only
  • ACTINIUM-225
Target(s):
  • SSTR2
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468